Literature DB >> 33593422

Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.

Rime Benmalek1, Hanane Mechal2, Hatim Zahidi2, Karim Mounaouir2, Salim Arous2, Mohamed El Ghali Benouna2, Abdenasser Drighil2, Rachida Habbal2.   

Abstract

BACKGROUND: Myeloproliferative neoplasms (MPNs) such as polycythemia Vera (PV) and Essential Thrombocythemia (ET) can be associated with a high risk of both venous and arterial thrombosis. However, the co-existence between these two complications is very rare and has never been described before, especially in young adults with no known history of MPNs. CASE
PRESENTATION: We report the case of a 39 year-old Caucasian Moroccan male patient without cardiovascular risk factors (CVRF), who presented with acute chest pain. He also suffered from a severe headache since 2 weeks. Electrocardiogram (ECG) showed ST segment elevation myocardial infarction in the posterolateral leads. Cerebral Computed Tomography (CT) scan revealed subarachnoid hemorrhage (SAH), and cerebral Magnetic Resonance Angiography (MRA) found a Superior Sagittal Sinus Thrombosis (SSST). Routine blood tests showed raised hemoglobin and hematocrit in addition to leukocytosis and thrombocythemia. His coronary angiography revealed a thrombus in the ostial left circumflex artery (LCX). Further testing revealed positive Janus kinase 2 (JAK2) V617F mutation and low erythropoietin level, confirming the diagnosis of PV according to the 2008 World Health Organization (WHO) criteria. Antithrombotic and anti-ischemic treatments, in addition to myelosuppressive therapy with hydroxyurea, were initiated with a good clinical and biological evolution.
CONCLUSION: This case shows that MPNs are an important cause of thrombosis, especially in young patients with no other risk factors. Early diagnosis and appropriate management are fundamental before the occurrence of life-threatening complications that can sometimes present in unusual forms associating arterial and venous thrombotic events.

Entities:  

Keywords:  Acute myocardial infarction; Cerebral venous thrombosis; Complications; Myeloproliferative neoplasms; Polycythemia vera; Young adult

Year:  2021        PMID: 33593422     DOI: 10.1186/s13256-020-02593-5

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  17 in total

1.  Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2014-10

Review 2.  Thrombosis of the cerebral veins and sinuses.

Authors:  Jan Stam
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

Review 3.  The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.

Authors:  Jerry L Spivak; Richard T Silver
Journal:  Blood       Date:  2008-04-09       Impact factor: 22.113

4.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Carlo Patrono; Raphael Marilus; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

5.  Coronary vasculopathy in polycythemia vera.

Authors:  B Hermanns; S Handt; J Kindler; L Füzesi
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 6.  Thrombotic disease in the myeloproliferative neoplasms.

Authors:  Anna Falanga; Marina Marchetti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

7.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

8.  Cardiovascular events and intensity of treatment in polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Giorgina Specchia; Rossella Cacciola; Riccardo Cavazzina; Daniela Cilloni; Valerio De Stefano; Elena Elli; Alessandra Iurlo; Roberto Latagliata; Francesca Lunghi; Monia Lunghi; Rosa Maria Marfisi; Pellegrino Musto; Arianna Masciulli; Caterina Musolino; Nicola Cascavilla; Giovanni Quarta; Maria Luigia Randi; Davide Rapezzi; Marco Ruggeri; Elisa Rumi; Anna Rita Scortechini; Simone Santini; Marco Scarano; Sergio Siragusa; Antonio Spadea; Alessia Tieghi; Emanuele Angelucci; Giuseppe Visani; Alessandro Maria Vannucchi; Tiziano Barbui
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

9.  Acute coronary disease in essential thrombocythemia and polycythemia vera.

Authors:  C Rossi; M L Randi; P Zerbinati; V Rinaldi; A Girolami
Journal:  J Intern Med       Date:  1998-07       Impact factor: 8.989

10.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Authors:  A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528

View more
  3 in total

1.  Polycythemia vera presenting with pulmonary embolism and splenic infarction: a case report.

Authors:  Ping Huang; Yuhong Li
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

2.  Cerebral venous sinus thrombosis as the initial presentation of essential thrombocythemia - A case report and literature review.

Authors:  Qudsum Yousaf; Haseeb Amad Khan; Fateen Ata; Adeel Ahmad Khan; Nadia Karim; Zohaib Yousaf
Journal:  eNeurologicalSci       Date:  2022-03-31

3.  Diagnose Aseptic Meningitis Caused by SARS-CoV-2 Vaccination Only After Ruling Out All Possible Differentials.

Authors:  Josef Finsterer
Journal:  Infect Chemother       Date:  2022-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.